UBS Group AG - BRIDGEBIO PHARMA INC ownership

BRIDGEBIO PHARMA INC's ticker is BBIO and the CUSIP is 10806X102. A total of 75 filers reported holding BRIDGEBIO PHARMA INC in Q3 2019. The put-call ratio across all filers is - and the average weighting 0.9%.

Quarter-by-quarter ownership
UBS Group AG ownership history of BRIDGEBIO PHARMA INC
ValueSharesWeighting
Q3 2023$4,023,272
+33.9%
152,570
-12.7%
0.00%0.0%
Q2 2023$3,004,513
+113.9%
174,681
+106.1%
0.00%0.0%
Q1 2023$1,404,956
-48.8%
84,738
-76.5%
0.00%0.0%
Q4 2022$2,742,270
+3016.2%
359,878
+3983.5%
0.00%
Q3 2022$88,000
-95.6%
8,813
-96.0%
0.00%
-100.0%
Q2 2022$2,008,000
-55.2%
221,077
-50.0%
0.00%0.0%
Q1 2022$4,487,000
+266.3%
442,040
+502.3%
0.00%
Q4 2021$1,225,000
-76.8%
73,387
-34.9%
0.00%
-100.0%
Q3 2021$5,283,000
+296.3%
112,725
+415.3%
0.00%
Q2 2021$1,333,000
+62.2%
21,875
+64.0%
0.00%
Q1 2021$822,000
-39.5%
13,341
-30.2%
0.00%
Q4 2020$1,359,000
+98.1%
19,118
+4.5%
0.00%
Q3 2020$686,000
+8.7%
18,295
-5.4%
0.00%
Q2 2020$631,000
+36.6%
19,344
+21.5%
0.00%
Q1 2020$462,000
-26.9%
15,920
-11.8%
0.00%
Q4 2019$632,000
-12.6%
18,041
-46.5%
0.00%
Q3 2019$723,000
+4418.8%
33,699
+5516.5%
0.00%
Q2 2019$16,0006000.00%
Other shareholders
BRIDGEBIO PHARMA INC shareholders Q3 2019
NameSharesValueWeighting ↓
Aisling Capital Management LP 6,068,125$55,099,00039.31%
M28 Capital Management LP 466,200$4,233,0004.74%
Kohlberg Kravis Roberts & Co. L.P. 31,060,971$282,034,0003.75%
Octagon Capital Advisors LP 933,743$8,478,0002.26%
VIKING GLOBAL INVESTORS LP 26,620,991$241,719,0001.11%
HHLR ADVISORS, LTD. 5,362,014$48,687,0001.04%
Cormorant Asset Management, LP 1,469,179$13,340,0001.01%
Knott David M Jr 213,206$1,936,0000.81%
Fernwood Investment Management, LLC 183,900$1,670,0000.72%
HighVista Strategies LLC 105,942$962,0000.58%
View complete list of BRIDGEBIO PHARMA INC shareholders